Acumen Pharmaceuticals (ABOS)

• Market cap: $64.3M
• 1 day: -2.73%
• 5 days: -11.57%
• 1 month: -6.96%
• 3 months: -42.16%
• 6 months: -56.33%
• Year to date: -42.16%
• 1 year: -73.32%
• 5 years: -94.68%
• 10 years: -94.68%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

8% more funds holding

Funds holding: 73 [Q3] → 79 (+6) [Q4]

1.95% less ownership

Funds ownership: 72.68% [Q3] → 70.73% (-1.95%) [Q4]

32% less capital invested

Capital invested by funds: $108M [Q3] → $73.1M (-$34.7M) [Q4]

68% less call options, than puts

Call options by funds: $64K | Put options by funds: $201K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 274% upside
• Avg. target: $7.50 601% upside
• High target: $11 928% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

UBS Colin Bristow 43% 1-year accuracy 6 / 14 met price target	274% upside $4	Buy Maintained	28 Mar 2025
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 358 met price target	928% upside $11	Buy Maintained	28 Mar 2025